APASL consensus statements and recommendation on treatment of hepatitis C

Creative Commons License

Omata M., Kanda T., Wei L., Yu M., Chuang W., Ibrahim A., ...Daha Fazla

HEPATOLOGY INTERNATIONAL, cilt.10, sa.5, ss.702-726, 2016 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 10 Sayı: 5
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1007/s12072-016-9717-6
  • Dergi Adı: HEPATOLOGY INTERNATIONAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.702-726
  • Anahtar Kelimeler: APASL, DAAs, HCV, Interferon-free, Turkey, VIRUS GENOTYPE 1, PEGYLATED INTERFERON-ALPHA, SOFOSBUVIR PLUS RIBAVIRIN, TREATMENT-NAIVE PATIENTS, SUSTAINED VIROLOGICAL RESPONSE, INTERLEUKIN-28B GENETIC-VARIANTS, TREATMENT-EXPERIENCED PATIENTS, PREVIOUSLY UNTREATED PATIENTS, FIXED-DOSE COMBINATION, OPEN-LABEL
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

The Asian-Pacific Association for the Study of the Liver (APASL) convened an international working party on the "APASL consensus statements and recommendation on management of hepatitis C" in March, 2015, in order to revise "APASL consensus statements and management algorithms for hepatitis C virus infection (Hepatol Int 6:409-435, 2012)". The working party consisted of expert hepatologists from the Asian-Pacific region gathered at Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed and debated to draft a revision. Participants of the consensus meeting assessed the quality of cited studies. Finalized recommendations on treatment of hepatitis C are presented in this review.